A Pocket Manual for Human Papillomavirus Vaccines

Authors

• Natalie A Voss
• J Brooks Jackson
• Mary B Rysavy

Language

English

Publication Date

3-4-2026

DOI

10.3390/vaccines14030236

PMID

41893773

PMCID

PMC13030634

PubMedCentral® Posted Date

3-4-2026

PubMedCentral® Full Text Version

Post-print

Abstract

Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and is responsible for the majority of cervical, anal, and vaginal cancers. The first prophylactic HPV vaccine was introduced in the United States in 2006. Extensive evidence demonstrates the HPV vaccine is highly efficacious and effective, particularly when administered prior to HPV exposure. Despite strong safety data and proven cost-effectiveness, HPV vaccine uptake in the United States and globally remains suboptimal. Barriers to vaccination include limited knowledge, safety concerns, and logistical challenges. Current advancements focus on single-dose vaccine regimens, development of therapeutic vaccines, and higher-valent formulations. Expanding HPV vaccine coverage is essential to reduce HPV-related diseases, strengthen herd immunity, and advance cancer prevention efforts.

Keywords

HPV vaccination, prevention, safety, efficacy, effectiveness, uptake

Published Open-Access

yes

Recommended Citation

Natalie A Voss, J Brooks Jackson, and Mary B Rysavy, "A Pocket Manual for Human Papillomavirus Vaccines" (2026). Faculty, Staff and Student Publications. 3907.
https://digitalcommons.library.tmc.edu/uthmed_docs/3907